HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
作者： Yoon-Sok Chung , Mi-Deok Lee , Seong-Kyu Lee , Hyeon-Man Kim , Lorraine A. Fitzpatrick
关键词:
摘要: Recently, it was reported that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors increased bone mineral density (BMD) in mice. We studied the effect of HMG-CoA on BMD type 2 diabetes mellitus by a retrospective review medical records. Sixty-nine diabetic patients were included. The control group (n = 33) did not take inhibitors. treatment 36) administered either lovastatin, pravastatin, or simvastatin. spine, femoral neck, trochanter, and total hip measured dual-energy X-ray absorptiometry. There no significant differences between groups age, sex, body mass index, glycemic control, serum insulin levels. In group, spine significantly decreased (from 1.116 ± 0.165 to 1.081 0.178 g/cm2) after 14 months. neck 0.853 0.139 0.878 0.147 15 I...
oup.com
endocrine.org
sci-hub.se 参考文章(20)
J. Ericsson, M. Runquist, A. Thelin, M. Andersson, T. Chojnacki, G. Dallner, Distribution of prenyltransferases in rat tissues. Evidence for a cytosolic all-trans-geranylgeranyl diphosphate synthase. Journal of Biological Chemistry. ,vol. 268, pp. 832- 838 ,(1993) , 10.1016/S0021-9258(18)54009-6
H E Meema, S Meema, The relationship of diabetes mellitus and body weight to osteoporosis in elderly females Canadian Medical Association Journal. ,vol. 96, pp. 132- 139 ,(1967)
H. Rico, E. R. Hernandez, J. A. Cabranes, F. Gomez-Castresana, Suggestion of a Deficient Osteoblastic Function in Diabetes Mellitus: The Possible Cause of Osteopenia in Diabetics Calcified Tissue International. ,vol. 45, pp. 71- 73 ,(1989) , 10.1007/BF02561404
J. E. Fisher, M. J. Rogers, J. M. Halasy, S. P. Luckman, D. E. Hughes, P. J. Masarachia, G. Wesolowski, R. G. G. Russell, G. A. Rodan, A. A. Reszka, Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 133- 138 ,(1999) , 10.1073/PNAS.96.1.133
C.Conrad Johnston, Siu L. Hui, Christopher Longcope, Bone mass and sex steroid concentrations in postmenopausal caucasian diabetics Metabolism. ,vol. 34, pp. 544- 550 ,(1985) , 10.1016/0026-0495(85)90192-1
Ruth S. Weinstock, Robin S. Goland, Elizabeth Shane, Thomas L. Clemens, Robert Lindsay, John P. Bilezikian, Bone mineral density in women with type II diabetes mellitus Journal of Bone and Mineral Research. ,vol. 4, pp. 97- 101 ,(2009) , 10.1002/JBMR.5650040114
Ermond Van Beek, Clemens Löwik, Gabri Van Der Pluijm, Socrates Papapoulos, The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen-Containing Bisphosphonates Journal of Bone and Mineral Research. ,vol. 14, pp. 722- 729 ,(1999) , 10.1359/JBMR.1999.14.5.722
G Mundy, R Garrett, S Harris, J Chan, D Chen, G Rossini, B Boyce, M Zhao, Gl Gutierrez, Stimulation of Bone Formation in Vitro and in Rodents by Statins Science. ,vol. 286, pp. 1946- 1949 ,(1999) , 10.1126/SCIENCE.286.5446.1946
Steven P. Luckman, Fraser P. Coxon, Frank H. Ebetino, R. Graham G. Russell, Michael J. Rogers, Heterocycle‐Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure‐Activity Relationships in J774 Macrophages Journal of Bone and Mineral Research. ,vol. 13, pp. 1668- 1678 ,(1998) , 10.1359/JBMR.1998.13.11.1668
M Terada, M Inaba, Y Yano, T Hasuma, Y Nishizawa, H Morii, S Otani, Growth-Inhibitory Effect of a High Glucose Concentration on Osteoblast-like Cells Bone. ,vol. 22, pp. 17- 23 ,(1998) , 10.1016/S8756-3282(97)00220-2